European Leukemia Trial Registry
Trial: CHOICES

More Details
Title Imatinib Versus Hydroxychloroquine and Imatinib in CML
Scientific Title A Randomized Phase II Trial of Imatinib (IM) Versus Hydroxychloroquine (HCQ) and IM for Patients With Chronic Myeloid Leukemia (CML) in Major Cytogenetic Response (MCyR) With Residual Disease Detectable by Quantitative Polymerase Chain Reaction (Q-PCR)
Short Title CHOICES
Trialgroup NN
Type of Trial randomized, prospective, open-label
Disease Chronic myeloid leukemia(CML) Chronic Phase
Age >= 18 years
Status Active
Start of Recruitment 01.03.2010
Leader Koschmieder, Prof. Dr. med., Steffen
Contactperson

General Contact Person Coordinating Investigator Germany
Koschmieder, Prof. Dr. med., Steffen
Tel: +49 (0)241 8036102
Fax: +49 (0)241 8082449
Email: skoschmieder@ukaachen.de

General Contact Person
Brümmendorf, Prof. Dr. med., Tim H.
Tel: +49 (0)241 80-89805
Fax: +49 (0)241 80-82449
Email: tbruemmendorf@ukaachen.de

Shortprotocol Shortprotocol
created 12.04.2013 Johannes Kraus
changed 09.11.2015 Zenawit Krüger
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org